Premium
Consensus recommendations on the use of daylight photodynamic therapy with methyl aminolevulinate cream for actinic keratoses in A ustralia
Author(s) -
See JoAnn,
Shumack Stephen,
Murrell Dedee F,
Rubel Diana M,
FernándezPeñas Pablo,
Salmon Robert,
Hewitt Daniel,
Foley Peter,
Spelman Lynda
Publication year - 2016
Publication title -
australasian journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.67
H-Index - 53
eISSN - 1440-0960
pISSN - 0004-8380
DOI - 10.1111/ajd.12354
Subject(s) - daylight , medicine , photodynamic therapy , actinic keratoses , dermatology , scalp , actinic keratosis , basal cell , optics , chemistry , physics , organic chemistry
A ustralia has the highest prevalence of actinic keratoses ( AK ) worldwide. Because of the risk of transformation of AK to invasive squamous cell carcinomas, consensus guidelines recommend that AK are removed using appropriate therapies to prevent progression to invasive disease. Daylight photodynamic therapy ( PDT ) is emerging as an efficacious treatment for AK , particularly for patients who require treatment of large areas of chronic actinic damage that can be exposed easily to daylight. Daylight PDT with methyl aminolevulinate ( MAL ) cream is a simple treatment for AK , almost painless, well tolerated and convenient, requiring minimal time in the clinic. Randomised controlled studies from northern E urope and A ustralia support the use of daylight PDT as an effective therapy for grade I and II AK on the face and scalp. There is sufficient daylight to conduct daylight PDT in A ustralia at any time of the year and during most weather conditions. Hence, daylight PDT with MAL can be included as an effective and well‐tolerated new treatment option for the treatment of AK in A ustralia. These consensus recommendations provide guidelines for Australian clinicians on the use of daylight PDT in the treatment of diagnosed AK .